2,555
Views
7
CrossRef citations to date
0
Altmetric
Original Articles

Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy

ORCID Icon, ORCID Icon, , , , , , , & show all
Pages 425-431 | Received 24 Mar 2021, Accepted 11 May 2021, Published online: 02 Jun 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Mehmet Koray Adali, Ipek Buber, Oguz Kilic, Anil Turkoz & Samet Yilmaz. (2022) Ticagrelor improves systemic immune-inflammation index in acute coronary syndrome patients. Acta Cardiologica 77:7, pages 632-638.
Read now

Articles from other publishers (6)

Stefano De Servi, Antonio Landi, Stefano Savonitto, Nuccia Morici, Leonardo De Luca, Claudio Montalto, Gabriele Crimi, Roberta De Rosa & Giuseppe De Luca. (2023) Antiplatelet Strategies for Older Patients with Acute Coronary Syndromes: Finding Directions in a Low-Evidence Field. Journal of Clinical Medicine 12:5, pages 2082.
Crossref
Stefano De Servi, Antonio Landi, Stefano Savonitto, Leonardo De Luca, Giuseppe De Luca, Nuccia Morici, Claudio Montalto, Gabriele Crimi & Marco Cattaneo. (2023) Tailoring oral antiplatelet therapy in acute coronary syndromes: from guidelines to clinical practice. Journal of Cardiovascular Medicine 24:2, pages 77-86.
Crossref
Ovidiu-Ionut Anchidin, Stefan Horia Rosianu, Ancuta Nemes, Mihai Aldica, Dan Blendea, Adrian Molnar, Horatiu Moldovan & Dana Pop. (2022) The Effectiveness of Antiplatelet Therapy and the Factors Influencing It in Patients with Acute Coronary Syndrome before and during the COVID-19 Pandemic. Medicina 59:1, pages 84.
Crossref
Dawn S. Kuszynski & D. Adam Lauver. (2022) Pleiotropic effects of clopidogrel. Purinergic Signalling 18:3, pages 253-265.
Crossref
Qi Feng, Man Fung Tsoi, Yue Fei, Ching Lung Cheung & Bernard M. Y. Cheung. (2021) Use of ticagrelor and the risks of pneumonia and pneumonia-specific death in patients with non-acute coronary syndrome conditions: a population-based cohort study. Scientific Reports 11:1.
Crossref
William A E Parker & Robert F Storey. (2021) Aspirin dosing for atherosclerotic cardiovascular disease: should we be more ADAPTABLE?. Cardiovascular Research 117:10, pages e123-e125.
Crossref